PolyNovo Limited (ASX:PNV): FY26 Revenue, NovoSorb Products and Regulatory Progress

Aditi Sarkar

22 October 2026 04:20 PM AEDT

PolyNovo Limited (ASX:PNV): FY26 Revenue, NovoSorb Products and Regulatory Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo Limited (ASX:PNV) reported FY26 total revenue of AUD 150.0 million, up 16.1%.
Commercial sales reached AUD 138.4 million, while FY26 EBITDA was AUD 12.1 million.
FY26 operating cash flow was AUD 23.1 million; year-end cash was AUD 35.4 million.
The company is progressing US regulatory submission activities for NovoSorb BTM.

PolyNovo Limited (ASX:PNV) develops and commercialises medical devices based on its proprietary NovoSorb polymer platform, used in the management of burns and complex wounds. The Melbourne-based company reported higher revenue and commercial sales for the year ended 30 June 2026 while advancing its manufacturing and regulatory programs. On 22 October 2026, PolyNovo Limited (ASX:PNV) was priced at AUD 0.893, down 0.83% for the trading session. Its FY26 results and planned US submissions place product adoption, cash generation and regulatory execution among the business's current monitoring points.

Company Business

PolyNovo's product range centres on NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. BTM is a synthetic matrix designed to support dermal reconstruction before definitive wound closure. MTX is a complementary dermal scaffold used in managing tissue deficits. Product selection and applications depend on applicable clearances and clinical circumstances.

The company sells into the Americas, Europe, the Middle East and Africa, and Asia-Pacific through direct operations and distribution arrangements. PolyNovo Limited (ASX:PNV) reported FY26 commercial sales of AUD 104.1 million in the Americas, AUD 20.6 million in EMEA and AUD 13.7 million in APAC. Its international structure exposes reported Australian-dollar results to currency movements as well as local clinical purchasing conditions.

Recent Development

In August 2026, PolyNovo released its FY26 results and updated its operating priorities. Construction of a new manufacturing facility was completed, with validation activities under way before the planned transition in FY27. The company also reported increased manufacturing output in the second half as production returned towards normal levels.

PolyNovo Limited (ASX:PNV) continued the commercial rollout of NovoSorb MTX and expanded clinical evidence relating to uses beyond burns. Its US pivotal trial clinical study report was finalised during 2026. Following updated US Food and Drug Administration guidance, the company revised sequencing of its premarket approval work for BTM in full-thickness burns. The company stated in May that submission was expected before the end of calendar 2026; submission and any later approval are distinct milestones.

The FY26 annual report identified priorities including expanding use in complex wounds, regulatory work, manufacturing transition and developing a broader product pipeline. These programs require clinical evidence, regulatory preparation and operational resources rather than relying solely on existing commercial distribution.

Financial Performance and Sector Context

For FY26, total revenue rose 16.1% to AUD 150.0 million from AUD 129.2 million in FY25. Commercial sales increased 16.7% to AUD 138.4 million from AUD 118.6 million, representing 21.3% growth on a constant-currency basis. These measures distinguish product sales from other reported revenue components.

PolyNovo Limited (ASX:PNV) reported FY26 EBITDA of AUD 12.1 million, compared with AUD 11.2 million in FY25. Net profit after tax declined to AUD 7.3 million from AUD 13.2 million. The company attributed the comparison partly to non-recurring effects and a change from an FY25 tax benefit to an FY26 tax expense. Gross margin declined to 89.0% from 95.6%, reflecting inventory movements.

Operating cash flow was AUD 23.1 million in FY26, against AUD 3.1 million in FY25. Free cash flow was AUD 9.4 million, and cash and cash equivalents reached AUD 35.4 million at 30 June 2026, versus AUD 33.5 million a year earlier. These figures indicate the relationship between sales expansion, profitability, working capital and investment in manufacturing infrastructure.

In the medical-device sector, hospital procurement, reimbursement policies, clinical evidence and regulatory permissions shape the practical adoption of wound-care products. PolyNovo's US market exposure makes product indications and reimbursement arrangements relevant to its operating conditions; regulatory submission does not itself establish authorisation or future demand.

Risks to Consider

Execution risk includes commissioning and validating the new manufacturing facility while maintaining product quality and supply continuity. Additional regulatory data requirements or delays could affect the timing of a US submission or review. PolyNovo Limited (ASX:PNV) also faces currency translation, hospital purchasing variability, product competition and the cost of building clinical evidence. Changes to reimbursement conditions or product access could affect use in particular care settings.

What to Watch Next

The next scheduled operating period includes FY27 trading updates, the transition of additional manufacturing capacity, the expansion of NovoSorb MTX and progress on clinical evidence. A key disclosed objective is the US BTM premarket approval submission; investors can distinguish the filing itself from subsequent FDA review and any decision. Monitoring sales mix, margin development and operating cash flow will also show how commercial activity translates into reported earnings.

Key Insights

PolyNovo Limited (ASX:PNV) closed FY26 with higher revenue and product sales, positive EBITDA and stronger operating cash flow, alongside a lower statutory net profit. The business continues to combine international distribution of NovoSorb products with regulatory development and manufacturing investment. FY27 disclosures on commercial sales, facility validation and the timing of regulatory milestones will provide the next measurable updates.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.